Clinical Trials
3 trialsNCT04924075 2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06202066 2026-05-28
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05988918 2026-05-14
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting